Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion.
暂无分享,去创建一个
Gennaro Ciliberto | R. Cortese | G. Ciliberto | J. Shiver | R. Bazzo | A. Pessi | E. Bianchi | P. Ingallinella | Michael D Miller | Riccardo Cortese | Elisabetta Bianchi | John W Shiver | Paolo Ingallinella | Gaetano Barbato | Antonello Pessi | Renzo Bazzo | G. Barbato | William H Hurni | M. Miller | W. Hurni | Michael D. Miller
[1] S. Grzesiek,et al. NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.
[2] Y. Hayek,et al. A monomeric 3(10)-helix is formed in water by a 13-residue peptide representing the neutralizing determinant of HIV-1 on gp41. , 2002, Biochemistry.
[3] R. Brüschweiler,et al. Multi-conformational peptide dynamics derived from NMR data: A new search algorithm and its application to antamanide , 1991, Journal of biomolecular NMR.
[4] C Leclerc,et al. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. , 2000, Vaccine.
[5] Nuclear Overhauser Effect , 2011 .
[6] S. Durell,et al. What studies of fusion peptides tell us about viral envelope glycoprotein-mediated membrane fusion (review). , 1997, Molecular membrane biology.
[7] A. Trkola,et al. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5 , 1996, AIDS.
[8] P S Kim,et al. Mechanisms of viral membrane fusion and its inhibition. , 2001, Annual review of biochemistry.
[9] A. Trkola,et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.
[10] E. Freed,et al. The Role of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins in Virus Infection (*) , 1995, The Journal of Biological Chemistry.
[11] K. Tan,et al. Atomic structure of a thermostable subdomain of HIV-1 gp41. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[12] J. Bradac,et al. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. , 1997, The Journal of infectious diseases.
[13] A. Trkola,et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. , 1994, AIDS research and human retroviruses.
[14] P. S. Kim,et al. A trimeric subdomain of the simian immunodeficiency virus envelope glycoprotein. , 1995, Biochemistry.
[15] Q. Sattentau,et al. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. , 1995, Virology.
[16] K. Guthrie,et al. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. , 1996, Biochemistry.
[17] E. Emini,et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[18] P. S. Kim,et al. HIV Entry and Its Inhibition , 1998, Cell.
[19] D. Hoekstra,et al. Peptides and Membrane Fusion: Towards an Understanding of the Molecular Mechanism of Protein-Induced Fusion , 1999, The Journal of Membrane Biology.
[20] S. Glaser,et al. A general enhancement scheme in heteronuclear multidimensional NMR employing pulsed field gradients , 1994, Journal of biomolecular NMR.
[21] R. Andrew Byrd,et al. ASSOCIATION OF BIOMOLECULAR SYSTEMS VIA PULSED FIELD GRADIENT NMR SELF-DIFFUSION MEASUREMENTS , 1995 .
[22] R. Garry,et al. A general model for the transmembrane proteins of HIV and other retroviruses. , 1989, AIDS research and human retroviruses.
[23] C. E. Parker,et al. Fine Definition of the Epitope on the gp41 Glycoprotein of Human Immunodeficiency Virus Type 1 for the Neutralizing Monoclonal Antibody 2F5 , 2001, Journal of Virology.
[24] B. Kemp,et al. Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure , 1995, Journal of virology.
[25] S. Nir,et al. The pre‐transmembrane region of the human immunodeficiency virus type‐1 glycoprotein: a novel fusogenic sequence , 2000, FEBS letters.
[26] H. Katinger,et al. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. , 1996, The Journal of general virology.
[27] A. Trkola,et al. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS , 1994, Journal of virology.
[28] David Neuhaus,et al. The Nuclear Overhauser Effect in Structural and Conformational Analysis , 1989 .
[29] A. Gronenborn,et al. Three‐dimensional solution structure of the 44 kDa ectodomain of SIV gp41 , 1998, The EMBO journal.
[30] S. Harrison,et al. Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.
[31] R. Sheppard,et al. Solid phase peptide synthesis : a practical approach , 1989 .
[32] L. Kelley,et al. An automated approach for clustering an ensemble of NMR-derived protein structures into conformationally related subfamilies. , 1996, Protein engineering.
[33] Q. Sattentau,et al. Inhibition of Virus Attachment to CD4+ Target Cells Is a Major Mechanism of T Cell Line–adapted HIV-1 Neutralization , 1997, The Journal of experimental medicine.
[34] G. Marius Clore,et al. The solution structure of a specific GAGA factor–DNA complex reveals a modular binding mode , 1997, Nature Structural Biology.
[35] J. Mascola,et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.
[36] J. Mascola,et al. Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.
[37] Eric Hunter,et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry , 1998, Nature Medicine.
[38] E. Hunter,et al. A Conserved Tryptophan-Rich Motif in the Membrane-Proximal Region of the Human Immunodeficiency Virus Type 1 gp41 Ectodomain Is Important for Env-Mediated Fusion and Virus Infectivity , 1999, Journal of Virology.
[39] K. Gunasekaran,et al. Beta-hairpins in proteins revisited: lessons for de novo design. , 1997, Protein engineering.
[40] H. Tian,et al. HIV epitope-peptides in aluminum adjuvant induced high levels of epitope-specific antibodies. , 2001, International immunopharmacology.
[41] Tahir A. Rizvi,et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.
[42] V. Hruby,et al. Conformations of the dermenkephalin backbone in DMSO solution by a new approach to the solution conformations of flexible peptides , 1993 .
[43] D. Montefiori. HIV-Specific Neutralizing Antibodies , 2001 .
[44] Paul W. H. I. Parren,et al. Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 , 2001, Journal of Virology.
[45] J. Shiver,et al. Enhancement of α-Helicity in the HIV-1 Inhibitory Peptide DP178 Leads to an Increased Affinity for Human Monoclonal Antibody 2F5 but Does Not Elicit Neutralizing Responses in Vitro , 2002, The Journal of Biological Chemistry.
[46] N. Sreerama,et al. A self-consistent method for the analysis of protein secondary structure from circular dichroism. , 1993, Analytical biochemistry.
[47] J. Shendure,et al. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. , 1999, Vaccine.
[48] Lǔ,et al. Multiepitope Vaccines Intensively Increased Levels of Antibodies Recognizing Three Neutralizing Epitopes on Human Immunodeficiency Virus‐1 Envelope Protein , 2000, Scandinavian journal of immunology.
[49] A. J. Shaka,et al. Water Suppression That Works. Excitation Sculpting Using Arbitrary Wave-Forms and Pulsed-Field Gradients , 1995 .
[50] B. Walker,et al. Retroviral immunology : immune response and restoration , 2001 .
[51] H. Vogel,et al. The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles. , 2001, Biochemistry.
[52] R. Bazzo,et al. NMR Analysis of Molecular Flexibility in Solution: A New Method for the Study of Complex Distributions of Rapidly Exchanging Conformations. Application to a 13-Residue Peptide with an 8-Residue Loop , 1995 .
[53] A. Agirre,et al. Membrane Interface-Interacting Sequences within the Ectodomain of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein: Putative Role during Viral Fusion , 2000, Journal of Virology.
[54] E. Arnold,et al. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints. , 2002, The journal of peptide research : official journal of the American Peptide Society.
[55] G Himmler,et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.
[56] H. Katinger,et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1 , 2002, AIDS.
[57] S. Zolla-Pazner,et al. Antibody Binding and Neutralization of Primary and T-Cell Line-Adapted Isolates of Human Immunodeficiency Virus Type 1 , 2001, Journal of Virology.
[58] A. Trkola,et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. , 1994, AIDS research and human retroviruses.
[59] Bruce A. Johnson,et al. NMR View: A computer program for the visualization and analysis of NMR data , 1994, Journal of biomolecular NMR.